文献速递药物不良反应与药物警戒

阿拉伯国家药物警戒体系概览:22国现状综述

Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries.
PubMed 文献 · Drug Saf · 2019-01-01

本文综述了22个阿拉伯国家药物警戒体系的现状与差异。仅45%的国家是WHO国际药物监测合作中心正式成员,摩洛哥、突尼斯、沙特、埃及、约旦被视为先进国家,而利比亚、也门、巴勒斯坦仍处早期,索马里、吉布提、毛里塔尼亚和科摩罗则无药物警戒体系或文化。

要点

  • 仅45%的阿拉伯国家是WHO国际药物监测合作中心正式成员。
  • 摩洛哥、突尼斯、沙特、埃及、约旦为药物警戒先进国家。
  • 利比亚、也门、巴勒斯坦仍处药物警戒体系早期阶段。

核心结论

  • 阿拉伯国家药物警戒体系发展不均衡,部分国家先进而部分国家仍处早期或无体系。

研究设计与样本

  • 本文为综述,覆盖22个阿拉伯国家,概述其药品监管机构与药物警戒体系现状。

主要发现

  • 仅45%的阿拉伯国家是WHO国际药物监测合作中心正式成员。
  • 摩洛哥、突尼斯、沙特阿拉伯、埃及和约旦被视为药物警戒先进国家。
  • 利比亚、也门和巴勒斯坦仍处于实施与开发药物警戒体系的非常早期阶段。
  • 索马里、吉布提、毛里塔尼亚和科摩罗岛没有药物警戒体系或文化。
  • 亚洲阿拉伯国家中50%属于海湾合作委员会(GCC),可借助相似方法开展药物警戒相关活动。

临床怎么用

  • 临床药学智能体在涉及阿拉伯国家药品不良反应报告或药物警戒数据时,应意识到各国体系成熟度差异显著。
  • 对来自无药物警戒体系或文化国家的药品安全信息,需谨慎评估其数据完整性与可靠性。

局限性

  • 本文为综述,未报告系统检索策略、纳入排除标准或定量合成方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacovigilance has received much attention in Arab countries recently due to the development of new regulations. However, there are differences in the progression of pharmacovigilance systems by regulatory agencies in these countries because only some are able to meet the requirements for conducting pharmacovigilance activities. Only 45% of Arab countries are official members of the World Health Organization (WHO) Collaborating Centre for International Drug Monitoring. Countries such as Morocco, Tunisia, Saudi Arabia, Egypt, and Jordan are considered to be advanced pharmacovigilance countries, whereas other countries such as Libya, Yemen, and Palestine remain in the very early stages of implementing and developing pharmacovigilance systems. Countries such as Somalia, Djibouti, Mauritania, and Comoros Island have no pharmacovigilance system or culture. Asian Arab countries have some advantages over those in Africa because 50% of them are a part of the Gulf Cooperation Council (GCC), meaning that most of them can utilize similar approaches for the application of the majority of activities related to the healthcare system, including pharmacovigilance. Thus, participating in the GCC enables increased connections among these countries. However, one of the strengths in Africa is that Morocco is partnering with the WHO through the WHO Collaborating Center to enhance and strengthen pharmacovigilance across the Eastern Mediterranean Region and the Francophone and Arab countries. This partnership could have a role in enhancing the pharmacovigilance culture among African Arab countries. This review provides a general overview of the current situation regarding regulatory agencies related to pharmacovigilance in Arab countries.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Alshammari TM, Mendi N, Alenzi KA, et al. Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries. Drug Saf. 2019. PMID: 31006085. doi:10.1007/s40264-019-00807-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。